As of May 25
| +0.0122 / +5.73%|
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 2.50, with a high estimate of 3.00 and a low estimate of 2.00. The median estimate represents a +1,011.11% increase from the last price of 0.23.
The current consensus among 2 polled investment analysts is to Buy stock in ImmunoCellular Therapeutics Ltd. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.